UY37505A - Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico - Google Patents
Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónicoInfo
- Publication number
- UY37505A UY37505A UY0001037505A UY37505A UY37505A UY 37505 A UY37505 A UY 37505A UY 0001037505 A UY0001037505 A UY 0001037505A UY 37505 A UY37505 A UY 37505A UY 37505 A UY37505 A UY 37505A
- Authority
- UY
- Uruguay
- Prior art keywords
- hyaluronic acid
- conjugates
- connector
- understanding
- glucagon agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Abstract
La presente invención se refiere a un conjugado o una de sus sales farmacéuticamente aceptables, que comprende un agonista del receptor de GLP-1/glucagón, un conector y un hidrogel de ácido hialurónico. La invención se refiere además a composiciones farmacéuticas que comprenden dicho conjugado, así como a su uso como medicamento para tratar o prevenir enfermedades o trastornos que pueden ser tratados mediante un agonista del receptor de GLP-1/glucagón.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306613 | 2016-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37505A true UY37505A (es) | 2018-06-29 |
Family
ID=57542941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037505A UY37505A (es) | 2016-12-02 | 2017-12-01 | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico |
Country Status (23)
Country | Link |
---|---|
US (2) | US10792367B2 (es) |
EP (1) | EP3548090A1 (es) |
JP (1) | JP2020503278A (es) |
KR (1) | KR20190091482A (es) |
CN (1) | CN110022902A (es) |
AR (1) | AR110299A1 (es) |
AU (1) | AU2017369723A1 (es) |
BR (1) | BR112019011139A8 (es) |
CA (1) | CA3045483A1 (es) |
CL (1) | CL2019001466A1 (es) |
CO (1) | CO2019006912A2 (es) |
CR (1) | CR20190312A (es) |
DO (1) | DOP2019000038A (es) |
EA (1) | EA201991316A1 (es) |
EC (1) | ECSP19046865A (es) |
IL (1) | IL266973A (es) |
MA (1) | MA46996A (es) |
MX (1) | MX2019006432A (es) |
PE (1) | PE20191472A1 (es) |
PH (1) | PH12019501215A1 (es) |
TW (1) | TW201832783A (es) |
UY (1) | UY37505A (es) |
WO (1) | WO2018100174A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
SG11201806092TA (en) | 2016-03-01 | 2018-08-30 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
HUE062009T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Bone Diseases As | Alacsony peak to trough arányú PTH vegyületek |
DK3518960T3 (da) | 2016-09-29 | 2023-09-04 | Ascendis Pharma Bone Diseases As | Doseringsskema for en PTH-forbindelse med kontrolleret frigivelse |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
SG11201908547VA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
KR20200037358A (ko) | 2017-08-09 | 2020-04-08 | 사노피 | 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제 |
TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物 |
FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
MX2022013230A (es) | 2020-04-24 | 2022-11-14 | Boehringer Ingelheim Int | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. |
KR102225971B1 (ko) * | 2020-05-19 | 2021-03-10 | 주식회사 차메디텍 | 펩타이드 가교제를 이용한 히알루론산 기반의 하이드로겔 및 이의 제조 방법 |
CN117677395A (zh) | 2021-07-30 | 2024-03-08 | 勃林格殷格翰国际有限公司 | 长效glp1/胰高血糖素受体激动剂的剂量方案 |
CN114470170B (zh) * | 2022-02-22 | 2023-09-19 | 广州新济药业科技有限公司 | 一种司美格鲁肽可溶性微针组合物及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5016926B2 (ja) * | 2003-12-30 | 2012-09-05 | ジェンザイム・コーポレーション | 架橋したヒアルロナンおよび/またはハイランに由来する粘着性ゲル、その調製および使用法 |
TW200612991A (en) * | 2004-09-07 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Process for producing water-soluble hyaluronic acid modification |
ES2458991T3 (es) | 2004-11-12 | 2014-05-07 | Novo Nordisk A/S | Formulaciones estables de péptidos insulinotrópicos |
CN101107270B (zh) * | 2004-11-24 | 2011-11-23 | 诺维信生物制药丹麦公司 | 用二乙烯基砜交联透明质酸的方法 |
EP2351776A1 (en) | 2005-06-13 | 2011-08-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
WO2008148839A2 (en) | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
EP2217701B9 (en) | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon antagonists |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
SI3050576T1 (sl) | 2008-04-29 | 2021-08-31 | Ascendis Pharma Endocrinology Division A/S | Spojine pegiliranega rekombinantnega humanega rastnega hormona |
TWI474832B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 胰高血糖素/glp-1受體共同激動劑 |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
MX2011006315A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
CA2747109A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
JP5738291B2 (ja) | 2009-07-31 | 2015-06-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリンリンカー複合体を含むプロドラッグ |
FR2952695B1 (fr) | 2009-11-13 | 2012-03-30 | Commissariat Energie Atomique | Reservoir de stockage d'hydrogene a hydrures metalliques |
KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
EP2552951A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
KR20130098873A (ko) | 2010-04-27 | 2013-09-05 | 질랜드 파마 에이/에스 | Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도 |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
CN102918177B (zh) | 2010-05-31 | 2015-09-09 | 株式会社捷太格特 | 覆盖部件的制造方法 |
WO2011152181A1 (ja) | 2010-06-01 | 2011-12-08 | 本田技研工業株式会社 | Dc/dcコンバータの制御装置 |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
EP2438930A1 (en) * | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
TWI601744B (zh) | 2011-06-17 | 2017-10-11 | 韓美科學股份有限公司 | 包含調酸素與免疫球蛋白片段之複合物及其用途 |
US20150316188A1 (en) | 2012-06-29 | 2015-11-05 | University Of South Australia | Fluid connection ports |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR094181A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
TW201609798A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Exendin-4胜肽類似物 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US10188759B2 (en) * | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
-
2017
- 2017-11-30 TW TW106141763A patent/TW201832783A/zh unknown
- 2017-11-30 AR ARP170103361A patent/AR110299A1/es unknown
- 2017-12-01 AU AU2017369723A patent/AU2017369723A1/en not_active Abandoned
- 2017-12-01 MA MA046996A patent/MA46996A/fr unknown
- 2017-12-01 JP JP2019529643A patent/JP2020503278A/ja not_active Abandoned
- 2017-12-01 PE PE2019001081A patent/PE20191472A1/es unknown
- 2017-12-01 KR KR1020197018576A patent/KR20190091482A/ko active Search and Examination
- 2017-12-01 EP EP17822168.5A patent/EP3548090A1/en active Pending
- 2017-12-01 CA CA3045483A patent/CA3045483A1/en not_active Abandoned
- 2017-12-01 CN CN201780074647.0A patent/CN110022902A/zh active Pending
- 2017-12-01 EA EA201991316A patent/EA201991316A1/ru unknown
- 2017-12-01 CR CR20190312A patent/CR20190312A/es unknown
- 2017-12-01 US US15/829,596 patent/US10792367B2/en active Active
- 2017-12-01 WO PCT/EP2017/081217 patent/WO2018100174A1/en unknown
- 2017-12-01 UY UY0001037505A patent/UY37505A/es not_active Application Discontinuation
- 2017-12-01 BR BR112019011139A patent/BR112019011139A8/pt not_active IP Right Cessation
- 2017-12-01 MX MX2019006432A patent/MX2019006432A/es unknown
-
2019
- 2019-02-21 DO DO2019000038A patent/DOP2019000038A/es unknown
- 2019-05-29 IL IL266973A patent/IL266973A/en unknown
- 2019-05-30 CL CL2019001466A patent/CL2019001466A1/es unknown
- 2019-05-31 PH PH12019501215A patent/PH12019501215A1/en unknown
- 2019-06-27 CO CONC2019/0006912A patent/CO2019006912A2/es unknown
- 2019-07-01 EC ECSENADI201946865A patent/ECSP19046865A/es unknown
- 2019-10-28 US US16/665,785 patent/US11141489B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CL2019001466A1 (es) | 2019-10-11 |
CO2019006912A2 (es) | 2020-04-24 |
AU2017369723A1 (en) | 2019-07-18 |
DOP2019000038A (es) | 2019-05-31 |
ECSP19046865A (es) | 2019-07-31 |
IL266973A (en) | 2019-07-31 |
CN110022902A (zh) | 2019-07-16 |
EA201991316A1 (ru) | 2019-10-31 |
WO2018100174A1 (en) | 2018-06-07 |
US11141489B2 (en) | 2021-10-12 |
TW201832783A (zh) | 2018-09-16 |
JP2020503278A (ja) | 2020-01-30 |
MA46996A (fr) | 2019-10-09 |
PH12019501215A1 (en) | 2019-08-19 |
AR110299A1 (es) | 2019-03-13 |
EP3548090A1 (en) | 2019-10-09 |
US10792367B2 (en) | 2020-10-06 |
KR20190091482A (ko) | 2019-08-06 |
US20200155688A1 (en) | 2020-05-21 |
US20180154005A1 (en) | 2018-06-07 |
BR112019011139A8 (pt) | 2020-03-24 |
PE20191472A1 (es) | 2019-10-16 |
BR112019011139A2 (pt) | 2019-10-01 |
CR20190312A (es) | 2019-09-11 |
CA3045483A1 (en) | 2018-06-07 |
MX2019006432A (es) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
CL2015002485A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
NZ743487A (en) | Controlled-release cnp agonists with increased nep stability | |
AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
PE20151005A1 (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
MX2016010599A (es) | Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. | |
UY36046A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
CY1122760T1 (el) | Τροποποιητης εξενατιδης και χρηση αυτου | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
EA201691964A1 (ru) | Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии | |
ECSP16094286A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230705 |